625 results on '"Grünig, Ekkehard"'
Search Results
2. Hereditäre pulmonal-arterielle Hypertonie
3. Erratum zu: Geschlechterspezifische Aspekte kardiovaskulärer Erkrankungen
4. Long-term oxygen therapy in precapillary pulmonary hypertension – SOPHA study
5. Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension
6. Genetic background of pulmonary (vascular) diseases – how much is written in the codes?
7. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis
8. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
9. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
10. Effect of Eccentric Cycling on Oxygen Uptake and Hemodynamics in Patients With Pulmonary Vascular Disease: A Randomized Controlled Crossover Trial
11. Submaximal, Low-Dose Eccentric vs Traditional Cycling Exercise: Reduced Oxygen Uptake and Pulmonary Artery Pressure Assessed by Echocardiography in Healthy Middle-aged Adults. A Randomized Controlled, Crossover Trial
12. Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension
13. Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study
14. Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension
15. Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial
16. An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
17. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension
18. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
19. The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review
20. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
21. Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
22. Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease
23. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis
24. Genetics of High-Altitude Pulmonary Edema
25. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
26. When Pulmonary Hypertension Complicates Heart Failure
27. Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis
28. Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
29. Pulmonale Hypertonie bei Erwachsenen mit angeborenen Herzfehlern im Lichte der 2022-ESC-PAH-Leitlinien: Part II: Supportive Therapie, Sondersituationen (Schwangerschaft, Kontrazeption, nicht-kardiale Operationen), zielgerichtete Pharmakotherapie, Organtransplantation, spezielles Management (Shuntvitien, Linksherzerkrankungen, univentrikuläre Herzen), Interventionen, Intensivmedizin, Nachsorge, Zukunftsperspektive
30. Age-changes in right ventricular function–pulmonary circulation coupling: from pediatric to adult stage in 1899 healthy subjects. The RIGHT Heart International NETwork (RIGHT-NET)
31. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
32. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
33. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
34. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry
35. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
36. Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study.
37. Air travel in patients suffering from pulmonary hypertension—A prospective, multicentre study.
38. Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
39. When Pulmonary Hypertension Complicates Heart Failure
40. Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
41. NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
42. Combined automated 3D volumetry by pulmonary CT angiography and echocardiography for detection of pulmonary hypertension
43. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
44. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension
45. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat
46. The Right Heart International Network (RIGHT-NET): Rationale, Objectives, Methodology, and Clinical Implications
47. Exercise Training and Rehabilitation in Pulmonary Hypertension
48. Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension
49. Author Correction: Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension
50. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.